Search results
Sarcoidosis is a systemic inflammatory granulomatous disease mainly affecting the lungs and thoracic lymph nodes. In a previous article in this journal, we reviewed emerging aspects of diagnosis and monitoring of the disease. This narrative paper aims to review and update sarcoidosis management.
Patients with sarcoidosis and precapillary pulmonary hypertension should be treated with therapies such as phosphodiesterase inhibitors and prostacyclin analogues.
12 kwi 2024 · The key questions regarding the initial treatment of sarcoidosis are the following: What are the indications for treatment? What is the initial treatment approach? What is the optimal duration of therapy?
29 lis 2022 · How to Treat Pulmonary Sarcoidosis Induction and Maintenance Phases of Treatment. Most experts agree that short courses (e.g. a few weeks) of high-dose corticosteroids are less useful than a longer course of lower dose treatment (total of > 6 months) for long-term remission [12, 41, 42••].
16 gru 2021 · Background: The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations.
1 lip 2016 · This review summarizes the recent discoveries regarding the pathogenesis of sarcoidosis, most common clinical presentations, diagnosis, and indications for treatment of pulmonary sarcoidosis.
1 mar 2022 · Patients with sarcoidosis and precapillary pulmonary hypertension should be treated with therapies such as phosphodiesterase inhibitors and prostacyclin analogues.
